Edition:
United States

Tenax Therapeutics Inc (TENX.OQ)

TENX.OQ on NASDAQ Stock Exchange Capital Market

0.34USD
16 Feb 2018
Change (% chg)

$-0.01 (-2.95%)
Prev Close
$0.36
Open
$0.36
Day's High
$0.36
Day's Low
$0.34
Volume
42,065
Avg. Vol
67,315
52-wk High
$0.84
52-wk Low
$0.30

Chart for

About

Tenax Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing products for the critical care market. The Company's main product is levosimendan. Levosimendan is a calcium sensitizer developed for intravenous use in hospitalized patients with acutely... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $9.72
Shares Outstanding(Mil.): 28.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 178.11 17.27
EPS (TTM): -- -- --
ROI: -- -1.15 35.43
ROE: -- -20.84 17.10

BRIEF-Tenax Therapeutics Announces Plan To Develop Levosimendan For A Pulmonary Hypertension Indication With No FDA Approved Therapies

* TENAX THERAPEUTICS ANNOUNCES PLAN TO DEVELOP LEVOSIMENDAN FOR A PULMONARY HYPERTENSION INDICATION WITH NO FDA APPROVED THERAPIES

Jan 16 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF80.80 +1.18
Merck & Co., Inc. (MRK.N) $56.29 +0.30
Roche Holding Ltd. (ROG.S) CHF225.50 +2.10
Roche Holding Ltd. (RO.S) CHF230.20 +2.60
Abbott Laboratories (ABT.N) $60.17 +0.67
Bayer AG (BAYGn.DE) €98.54 +1.15
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €64.50 +1.00
Eli Lilly and Co (LLY.N) $78.97 +0.95
Bristol-Myers Squibb Co (BMY.N) $68.96 -0.02

Earnings vs. Estimates